4+ day, 21+ hour ago   (228+ words) The Pharma Letter MannKind inks obesity deal with Rose Pharma US biopharma company MannKind Corp (Nasdaq: MNKD) and Rose Pharma today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management....

4+ day, 22+ hour ago   (230+ words) The Pharma Letter - Kura launches new company, diabetes focused Caspian Therapeutics US biotech Kura Oncology (Nasdaq: KURA) today announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian…...

2+ week, 3+ day ago   (216+ words) The Pharma Letter - Galen and POA Pharma launch Galsana, a new global brand for rare metabolic diseases Northern Ireland-headquartered pharma company Galen has unveiled Galsana, a new global brand uniting its metabolic disease portfolio with that of Copenhagen-based POA Pharma,…...

2+ week, 5+ day ago   (251+ words) The Pharma Letter - Russia’s Circle of Goodness Foundation increases procurements of most expensive drugs The Circle of Goodness Foundation, the Russian public fund, which specializes on the procurements of the most expensive drugs, has significantly increased its procurements this year....

2+ week, 5+ day ago   (255+ words) The Pharma Letter - Russia’s Geropharm is seeking legal action to use five Novo Nordisk patents The Russian drugmaker Geropharm is seeking legal action to use five patents held by Danish company Novo Nordisk (NOV: N), which are related to semaglutide....

2+ week, 6+ day ago   (227+ words) The Pharma Letter - Revier launches with six million euros seed round to develop class IIa HDAC inhibitors for cardiometabolic disease German biotech Revier Therapeutics has launched operations following the close of a six million euros ($6.45 million) seed financing round, the…...

2+ week, 6+ day ago   (235+ words) The Pharma Letter - Hanmi Pharm inks obesity license deal with Genentech South Korean firm Hanmi Pharm (KRX: 128940) today announced that it has entered into an exclusive licensing agreement with Swiss pharma giant Roche’s (ROG: SIX) subsidiary Genentech, for the development,…...

3+ week, 2+ day ago   (588+ words) The Pharma Letter A clinical-stage biopharmaceutical company focused on WEE1 inhibition in biomarker-selected ovarian cancer, with its lead asset azenosertib approaching a pivotal registration-enabling data readout in 2026. Zentalis Pharmaceuticals discovers and develops small molecule therapeutics targeting fundamental biological pathways in cancer....

3+ week, 4+ day ago   (260+ words) The Pharma Letter - Pharma in hackers' crosshairs as Amgen breach moves to courts USA-based biotech major Amgen (Nasdaq: AMGN) is now defending a proposed class action over the cloud breach it disclosed in late July, the first sign that an…...